Study Evaluating the Safety, Tolerability and Efficacy of PBT2 in Patients With Early Alzheimer's Disease

A 12-Week, Randomised, Double-Blind, Placebo-Controlled, Parallel Three-Group Study to Assess the Safety, Tolerability and Efficacy of Two Dose Levels of PBT2 to Slow Progression of Disease in Patients With Early Alzheimer's Disease

The purpose of the study is to determine the safety, tolerability and efficacy of 2 doses of PBT2 administered for 12 weeks compared to placebo in patients with early Alzheimer's disease treated with an acetylcholinesterase inhibitor.

Inclusion Criteria:

• diagnosis of probable early Alzheimer's disease
• stable dose of acetylcholinesterase inhibitor
• community dwelling
• stable medical condition

Exclusion Criteria:

• unstable and significant medical conditions
• recurrent major psychiatric disorder
• treatment with memantine